<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01013688</url>
  </required_header>
  <id_info>
    <org_study_id>Wangxin</org_study_id>
    <nct_id>NCT01013688</nct_id>
  </id_info>
  <brief_title>Efficiency of Radiofrequency Ablation for Surgical Treatment of Chronic Atrial Fibrillation With Rheumatic Valve Disease</brief_title>
  <official_title>Efficiency of Radiofrequency Ablation for Surgical Treatment of Chronic Atrial Fibrillation With Rheumatic Valve Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether concomitant radiofrequency Maze procedure&#xD;
      for surgical treatment of chronic atrial fibrillation with rheumatic valve disease could&#xD;
      provide better sinus rhythm control, improved cardiac hemodynamic status and decreased&#xD;
      thromboembolism events and to compare if biatrial is better than left atrial procedure? 150&#xD;
      rheumatic valve patients with chronic atrial fibrillation (AF) having concomitant valve&#xD;
      surgery were randomized to three groups: left atrial ablation group, bi-atrial ablation&#xD;
      group, and Amiodarone group. All patients were scheduled followed up before discharge and at&#xD;
      3rd, 6th and 12th postoperative months. Standard 12-lead electrocardiography (ECG), 24-hour&#xD;
      Holter and transthoracic echocardiography were used to determine the rhythm and cardiac&#xD;
      hemodynamic status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether concomitant radiofrequency Maze procedure&#xD;
      for surgical treatment of chronic atrial fibrillation with rheumatic valve disease could&#xD;
      provide better sinus rhythm control,improved cardiac hemodynamic status and decreased&#xD;
      thromboembolism events and to compare if biatrial is better than left atrial procedure?&#xD;
&#xD;
      150 patients with chronic AF having concomitant cardiac surgery will be enrolled. Patients&#xD;
      will underwent bi-atrial radiofrequency,left atrial radiofrequency or no radiofrequency&#xD;
      procedure randomly. All the patients will receipt amiodarone 200 mg/day for 12 months&#xD;
      postoperatively.&#xD;
&#xD;
      All patients were scheduled followed before discharge and at 3rd, 6th and 12th postoperative&#xD;
      months.The following diagnostic procedures were performed&#xD;
&#xD;
        1. Standard 12-lead electrocardiography&#xD;
&#xD;
        2. Holter-ECG&#xD;
&#xD;
        3. Transthoracic echocardiography&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>At 3rd, 6th and 12th month's follow-up, to evaluate the rhythm status by ECG and 24-hour Holter and cardiac hemodynamic status by transthoracic echocardiography</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Rheumatic Valve Disease</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>left atrial RF ablation groups</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Excised the left atrial appendage Encircling the left pulmonary veins and an extension to the posterior mitral valve annulus From the left atrial appendage to the left superior pulmonary vein A connecting line between both islands of pulmonary veins From the middle of the mitral valve ablation line down towards the base of the atria ligament of Marshall</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bi-atrial radiofrequency ablation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the basis of left atrial group,excised the right atrial appendage; from the amputated right atrial appendage towards the inferior vena cava; from the midterm of interatrial septum to the AV groove; ablation between the superior and inferior caval cannulation sites; radiofrequency ablation for Waterston's groove</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amiodarone group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No radiofrequency ablation procedure during the valve surgery; Amiodarone 200 mg/day for 12 months after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardioblate® Surgical Ablation System</intervention_name>
    <description>Using Cardioblate® Surgical Ablation System to perform left atrial or bi-atrial radiofrequency ablation procedure during valve surgery</description>
    <arm_group_label>Bi-atrial radiofrequency ablation group</arm_group_label>
    <arm_group_label>left atrial RF ablation groups</arm_group_label>
    <other_name>radiofrequency</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with atrial fibrillation secondary to definite rheumatic valve disease&#xD;
&#xD;
          2. At least six months and no longer than 5 years of chronic atrial fibrillation&#xD;
&#xD;
          3. Age &gt;=18 years and &lt;=70 Patients who can give informed consent themselves in writing&#xD;
&#xD;
          4. No contraindication for amiodarone&#xD;
&#xD;
          5. Negative pregnancy test (in women with childbearing potential)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any one of the following exclusion criteria is sufficient to disqualify a patient from the&#xD;
        study&#xD;
&#xD;
          1. Left atrial diameter(LAD)&gt;=70mm&#xD;
&#xD;
          2. Left ventricular eject fraction(LVEF)&lt;=30%&#xD;
&#xD;
          3. Atrial thrombus&#xD;
&#xD;
          4. Contraindication for anticoagulation therapy&#xD;
&#xD;
          5. Less than 6 months since last episode of cerebral infarction&#xD;
&#xD;
          6. Emergency operation&#xD;
&#xD;
          7. Patients with a malignant tumor&#xD;
&#xD;
          8. Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming&#xD;
             pregnant before the end of the study period.&#xD;
&#xD;
          9. Any other reason that the Clinical Supervisors or Clinical Researchers may have for&#xD;
             considering a case unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengshou Hu</last_name>
    <role>Study Director</role>
    <affiliation>National center for cardiovascular disease ,china</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xin Wang, MD</last_name>
    <phone>86 10 15810210252</phone>
    <email>liuyedao21st@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuwai cardiovascular disease hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wangxin, MD</last_name>
      <phone>86 10 15810210252</phone>
      <email>liuyedao21st@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>November 11, 2009</study_first_submitted>
  <study_first_submitted_qc>November 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2009</study_first_posted>
  <last_update_submitted>November 16, 2009</last_update_submitted>
  <last_update_submitted_qc>November 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>China National Center for Cardiovascular Diseases</name_title>
    <organization>China National Center for Cardiovascular Diseases</organization>
  </responsible_party>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Maze</keyword>
  <keyword>Atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

